VILEVEV MB- methenamine, phenyl salicylate, sodium phosphate, monobasic, anhydrous, methylene blue anhydrous, and hyoscyamine su

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV), PHENYL SALICYLATE (UNII: 28A37T47QO) (PHENYL SALICYLATE - UNII:28A37T47QO), SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS (UNII: KH7I04HPUU) (PHOSPHATE ION - UNII:NK08V8K8HR), METHYLENE BLUE ANHYDROUS (UNII: 8NAP7826UB) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH), HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X)

Commercializzato da:

Vilvet Pharmaceuticals Inc

INN (Nome Internazionale):

METHENAMINE

Composizione:

METHENAMINE 81 mg

Via di somministrazione:

ORAL

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

VILEVEV MB is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections and antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. VILEVEV MB is contraindicated in patients with a hypersensitivity to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). A dependence on the use of VILEVEV MB has not been reported and due to the nature of its ingredients, abuse of VILEVEV MB is not expected.

Stato dell'autorizzazione:

unapproved drug other

Scheda tecnica

VILEVEV MB- METHENAMINE, PHENYL SALICYLATE, SODIUM PHOSPHATE,
MONOBASIC, ANHYDROUS,
METHYLENE BLUE ANHYDROUS, AND HYOSCYAMINE SULFATE TABLET
VILVET PHARMACEUTICALS INC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
VILEVEV MB TABLETS
Rx Only
Each tablet contains:
METHENAMINE
81.0 mg
SODIUM PHOSPHATE MONOBASIC
40.8 mg
PHENYL SALICYLATE
32.4 mg
METHYLENE BLUE
10.8 mg
HYOSCYAMINE SULFATE
0.12 mg
Inactive Ingredients: Microcrystalline Cellulose, Croscarmellose
Sodium, Magnesium Stearate, Stearic
acid.
METHENAMINE. [100-97-0] 1, 3, 5, 7 – Tetraazatricyclo [3.3.1.-1
] decane; hexamethylenetetramine;
HMT; HMTA; hexamine; 1, 3, 5, 7- tetraazaadamantane hexamethylenemine;
Uritone; Urotropin.
C H N ; mol wt 140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine
(hexamethylenetetramine)
exists as colorless, lustrous crystals or white crystalline powder.
Its solutions are alkaline to litmus.
Freely soluble in water, soluble in alcohol and chloroform.
SODIUM PHOSPHATE MONOBASIC. [7558-80-7] Phosphoric acid sodium salt
(1:1); Sodium
biphosphate; sodium dihydrogen phosphate; acid sodium phosphate;
monosodium orthophosphate;
primary sodium phosphate; H NaO P; mol wt 119.98, H 1.68%, Na 19.16%,
O 53.34%, P 25.82 %.
Monohydrate, white, odorless slightly deliquesce crystals or granules.
At 100 °C loses all its water;
when ignited it converts to metaphosphate. It is freely soluble in
water and practically insoluble in
alcohol. The aqueous solution is acid. pH of 0.1 molar aqueous
solution at 25 °C; 4.5.
PHENYL SALICYLATE. [118-55-8] 2-Hydroxybenzoic acid phenyl ester;
Salol. C
H O ; mol wt
214.22, C 72.89%, H 4.71%, O 22.41%. Made by the action of phosphorous
oxy-chloride on a mixture
of phenol and salicylic acid. Phenyl Salicylate exists as white
crystals with a melting point of 41° -
43°C. It is very slightly soluble in water and freely soluble in
alcohol.
METHYLENE BLUE. [61-73-4] 3